Tid Tittel Kategori Vedlegg
06.05.2026
07:00
 New Phase II Study Data from Lytix Biopharma’s Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma - -
21.04.2026
16:00
 Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 - -
21.04.2026
07:00
 Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma -
1
16.04.2026
23:18
 Lytix Biopharma ASA – Conversion to public limited liability company and name change registered - -
14.04.2026
17:07
 Lytix Biopharma AS: Minutes from Annual General Meeting -
1
09.04.2026
20:52
 Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS INSIDEHANDEL INS
1
07.04.2026
07:00
 Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth -
1
25.03.2026
09:14
 Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 -
1
24.03.2026
07:03
 Lytix Biopharma AS: Annual Report for 2025 RAPPORT RAP
1
18.03.2026
07:00
 Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026 - -
24.02.2026
12:16
 Lytix Biopharma AS - New share capital registered - -
17.02.2026
08:49
 Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC) - -
12.02.2026
07:00
 Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report RAPPORT RAP
2
10.02.2026
19:04
 Lytix Biopharma AS – Final result of Subsequent Offering and allocation of Offer Shares - -
10.02.2026
07:00
 Lytix Biopharma AS – Last day of the Subscription Period in the Subsequent Offering - -
05.02.2026
12:16
 Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report - -
27.01.2026
10:49
 Lytix Biopharma AS – Publication of Prospectus regarding Subsequent Offering and commencement of Subscription Period - -
26.01.2026
17:32
 Lytix Biopharma AS – EGM minutes - Subsequent Offering, ASA Conversion, Board Expansion and Board Authorization Approved -
1
14.01.2026
17:08
 Lytix Biopharma AS - New share capital registered - -
12.01.2026
11:52
 Lytix Biopharma AS – Notice of extraordinary general meeting 26 January 2026 -
1
09.01.2026
11:50
 Lytix Biopharma AS – Mandatory notification of trade by close associate of primary insider INSIDEHANDEL INS
1
09.01.2026
07:58
 Lytix Biopharma AS: Key information relating to potential subsequent offering - -
09.01.2026
07:49
 Lytix Biopharma AS: Private placement successfully completed with oversubscription INFORMASJON INF -
11.12.2025
13:39
 LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER INSIDEHANDEL INS
1
18.11.2025
07:00
 Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy RAPPORT RAP
2